C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
12/2006
12/28/2006	US20060294614 Orphan receptors; drug screening; host cells
12/28/2006	US20060294612 Gpcr-like retinoic acid-induced gene 1 protein and nucleic acid
12/28/2006	US20060294611 WIP, a WASP-associated protein
12/28/2006	US20060294608 Novel haemopoietin receptor and genetic sequences encoding same
12/28/2006	US20060294607 Human podocalyxin alternative-spliced forms and uses thereof
12/28/2006	US20060294605 Novel human dickkopf-related protein and nucleic acid molecules and uses therefor
12/28/2006	US20060294604 Model for studying the role of genes in tumor resistance to chemotherapy
12/28/2006	US20060294602 Diagnostic and therapeutic use of a rab family gtp-binding protein for neurodegenerative diseases
12/28/2006	US20060293512 Novel human uncoupling proteins and polynucleotides encoding the same
12/28/2006	US20060293507 Crystallization of IGF-1
12/28/2006	US20060293505 Crystal of a truncated protein construct containing a coagulation factor VIII C2 domain in the presence or absence of a bound ligand and methods of use thereof
12/28/2006	US20060293254 Podophyllotoxin
12/28/2006	US20060293239 Treatment and Diagnosis of Insulin-Resistant States
12/28/2006	US20060293238 Inactivation resistant factor VIII
12/28/2006	US20060293237 an octapeptide that selectively activates the Receptors for Activated C-Kinase (RACK) in cardiomyocytes and is linked to a tat-peptide or polyarginine peptide; peptide can be administered before, during or after the ischemic or hypoxic events; antiischemic, antihypoxic agents
12/28/2006	US20060293235 HGF beta chain variants
12/28/2006	US20060293234 Interaction between MUC1 and beta -catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUC1, whereby interruption provides the beneficial effect of inhibiting, reducing, and/or retarding invasiveness and metastasis
12/28/2006	US20060293232 Hybrid polypeptides with selectable properties
12/28/2006	US20060293230 Expression and secretion of icIL-1 receptor antagonist type II
12/28/2006	US20060293225 Gmg-2 polynucleotides and polypeptides and uses thereof
12/28/2006	US20060293224 Conformationally stabilized cell adhesion peptides
12/28/2006	US20060293221 Mucosal repair by TFF2 peptides
12/28/2006	US20060293219 Methods of treating diabetes mellitus
12/28/2006	US20060292687 Methods for modulating floral organ identity, modulating floral organ number, increasing of meristem size, and delaying flowering time
12/28/2006	US20060292671 utilizes mannitol, arabitol, glucitol, or glycerol to induce expression of a target polypeptide from an inducible promoter, allowing for the use of an inexpensive and stable carbon source inducer in the fermentation processes for the production of recombinant peptides
12/28/2006	US20060292670 Nell peptide expression systems and bone formation activity of nell peptide
12/28/2006	US20060292669 Mammalian prickle gene
12/28/2006	US20060292668 Nuclear factor of activated t cell receptor
12/28/2006	US20060292667 Method for improving solubility and folding efficiency of target proteins using RNA as molecular chaperone
12/28/2006	US20060292659 Binding a polypeptide having an anchor region and a protease recognition site to a solid support comprising a protein via a protein-protein interaction; industrial scale drug screening for hepatitis C protease inhibitors; high speed
12/28/2006	US20060292648 Screening for target that disrupts interaction between human osteopontin (OPN) and an alpha 4 integrin; inflammatory diseases
12/28/2006	US20060292639 Splice variant of the vanilloid receptor VR1A
12/28/2006	US20060292634 Structure for presenting desired peptide sequences
12/28/2006	US20060292633 Method for modulating process mediated by farnesoid activated receptors
12/28/2006	US20060292631 Elastin peptide fingerprints and analysis methods for mmp12 related to copd
12/28/2006	US20060292629 Chimeric polypeptides and their use
12/28/2006	US20060292627 PB39, a gene dysregulated in prostate cancer, and uses thereof
12/28/2006	US20060292625 Novel human leucine-rich repeat domain containing protein HLLRCR-1
12/28/2006	US20060292622 determining the presence of or predisposition to early-onset spinocerebellar ataxia with ocular motor aprataxia and hypoalbuminemia in a human; neurodegenerative disease
12/28/2006	US20060292620 Genes with ES cell-specific expression
12/28/2006	US20060292613 Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions
12/28/2006	US20060292609 Interferon-beta gene therapy using an improved, regulated expression system
12/28/2006	US20060292593 Nucleotide sequences coding B7 immune response regulatory protein selectively expressed on dendritic cells for use as therapeutic tool in targeting viral and tumor cell for destruction
12/28/2006	US20060292591 Genes from the 20q13 amplicon and their uses
12/28/2006	US20060292590 NOD nucleic acids and polypeptides
12/28/2006	US20060292587 Polynucleotides encoding insect voltage-gated chloride channel and uses thereof
12/28/2006	US20060292581 Biosensor for small molecule analytes
12/28/2006	US20060292577 Neoplasia-specific splice variants and methods
12/28/2006	US20060292573 Human orthologues of WART
12/28/2006	US20060292560 Transcription factor target gene discovery
12/28/2006	US20060292557 contacting a biological sample suspected of containing anti-herpes simplex virus type-2 (HSV-2) antibodies with an antigen comprising a nonapeptide and with a second antigen capable of binding specific anti-HSV-2 antibody, to detect the presence or absence of a specific anti-HSV-2 antibody
12/28/2006	US20060292556 Method of detecting antibodies to HCV
12/28/2006	US20060292554 Major coat protein variants for C-terminal and bi-terminal display
12/28/2006	US20060292551 cationic peptides useful in the treatment of dermatitis and viral infections; for topical administration
12/28/2006	US20060292548 Using channel protein and immobilized nerve to identify inhibitors of bitter and/or sweet taste preception
12/28/2006	US20060292546 Herg channel-expressing cell
12/28/2006	US20060292180 Contacting the sample with an isolated antibody specific for an EspA polypeptide, wherein the polypeptide is a secreted protein from enteropathogenic E. coli, detecting binding of the antibody to EspA polypeptide
12/28/2006	US20060292178 Proteins encoded by the severe acute respiratory syndrome (SARS) coronavirus and a role in apoptosis
12/28/2006	US20060292177 Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
12/28/2006	US20060292175 Chimeric alphavirus replicon particles
12/28/2006	US20060292169 Fusion proteins of mycobacterium tuberculosis antigens and their uses
12/28/2006	US20060292168 Methylated heparin-binding hemagglutinin recombinant mycobacterial antigen, preparation method and immunogenic compositions comprising same
12/28/2006	US20060292161 Protective epitopes of adenyl cyclase-haemolysin (AC-Hly), their application to the treatment or to the prevention of bordetella infections
12/28/2006	US20060292157 MDA-7 protein variants having antiproliferative activity
12/28/2006	US20060292153 Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders
12/28/2006	US20060292150 Methods of using wisp antagonists
12/28/2006	US20060292146 Isolated PTPMT1 protein which mediates insulin production and uses thereof
12/28/2006	US20060292144 Human disintegrin protein
12/28/2006	US20060292143 Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
12/28/2006	US20060292140 Humanized immunoglobulin reactive with alpha4beta7 integrin
12/28/2006	US20060292139 Eukaryotic host cell containing a nucleic acid sequence coding for a bivalent or a multivalent glycosylated compound having two or more single polypeptide chain antigen binding regions linked to a prodrug-activating enzyme; transgenic nonhuman mammal having the sequence
12/28/2006	US20060292123 Adeno-associated virus-mediated delivery of GDNF to skeletal muscles
12/28/2006	US20060292118 Hollow nanoparticles of protein and drug using the same
12/28/2006	US20060292117 Improved rAAv vectors
12/28/2006	US20060292116 Reduced vasopermeability activity and similar binding affinity for an IL-2 receptor compared to its wildtype form; immunostimulants; immuotherapy; anticarcinogenic agents; renal cell cancer, melanoma; chemotherapy and/or radiation therapy; viricides; human immunodeficiency virus; autoimmune disorders
12/28/2006	US20060292114 Neurturin receptor
12/28/2006	US20060292075 Labelled glutamine and lysine analogues
12/28/2006	DE102005028271A1 Use of protein mixture comprising G-proteins of vesicular stomatitis virus and membrane-constant antigen, which are derived from cytoplasmic replication viruses, to induce/increase the immune reaction against membrane-constant antigen
12/28/2006	DE102005027139A1 Neue Cystein-verarmte Hydrophobinfusionsproteine, deren Herstellung und Verwendung New cysteine-depleted hydrophobin, their preparation and use
12/28/2006	DE102005025969A1 Reduction of evaporation rate of water in an open water reservoir, comprises mixing of hydrophobin fusion protein with water and/or biodegradable barrier liquid having hydrocarbon mixture
12/28/2006	CA2648732A1 Supravalent compounds
12/28/2006	CA2633030A1 Intralesional treatment of psoriasis
12/28/2006	CA2613480A1 Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
12/28/2006	CA2613257A1 A novel biological substance nesfatin and its related substances and uses thereof
12/28/2006	CA2612900A1 Tuberculosis vaccines comprising antigens expressed during the latent infection phase
12/28/2006	CA2612516A1 Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
12/28/2006	CA2612494A1 Epitope analogues
12/28/2006	CA2612458A1 Use of hydrophobin-polypeptides and conjugates from hydrophobin-polypeptides having active and effect agents and the production thereof and use thereof in the cosmetic industry
12/28/2006	CA2612417A1 Anti-gfralpha3 antibodies
12/28/2006	CA2612302A1 Immunoreactive protein orthologs of ehrlichia canis and e. chaffeensis
12/28/2006	CA2612240A1 Genes of an otitis media isolate of nontypeable haemophilus influenzae
12/28/2006	CA2611924A1 Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection
12/28/2006	CA2611823A1 Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
12/28/2006	CA2610931A1 Anchored transferrin fusion protein libraries
12/28/2006	CA2608278A1 Immunogenic compositions for chlamydia trachomatis
12/27/2006	EP1736775A1 Novel ligand of g protein coupled receptor protein and use thereof
12/27/2006	EP1736547A1 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation
12/27/2006	EP1736545A2 Soluble zcytor 11 cytokine receptors
12/27/2006	EP1736544A1 Gm1 PROMOTER AND USE THEREOF
12/27/2006	EP1736541A1 Novel galectin 9 modification protein and use thereof

1 ... 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 ... 2916